Navigation Links
iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs
Date:3/12/2008

NASHUA, N.H., March 12 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early detection of cancer, today announced that John DeLucia has joined iCAD as the Vice President of Quality Assurance and Regulatory Affairs, reporting to iCAD President and CEO Ken Ferry. Mr. DeLucia brings more than 25 years of medical device, in-vitro diagnostics and biomedical research experience to this key management position. Mr. DeLucia has significant experience working with the FDA and other global regulatory authorities, and will be responsible for navigating iCAD through several anticipated FDA milestones. His expertise includes managing and directing regulatory submissions, compliance, clinical studies, quality assurance and laboratory services for medical device and clinical diagnostic products.

"We are delighted to have John join iCAD's management team," said Ken Ferry. "We are confident that John's experience and successful track record with the FDA and other regulatory agencies will be of tremendous value to iCAD as we execute on our growth strategy and bring new products to market."

"I am especially pleased to be joining iCAD at this exciting time, as we have an opportunity to bring several compelling cancer screening technologies through the regulatory process and on to commercialization," said Mr. DeLucia. "I look forward to being an integral part of iCAD's success."

Prior to joining iCAD, Mr. DeLucia served as Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance at Z-Tech Medical Inc., a medical device company that developed a novel bioimpedance breast scanning detection system. Mr. DeLucia was responsible for directing and managing clinical trials, global regulatory submissions, facility quality operations and reporting, and regulatory compliance activities.

Before joining Z-Tech Medical Inc., Mr. DeLucia was Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance at Microsulis Americas, Inc., a medical device company that manufactures endometrial ablation systems for gynecological markets worldwide. Prior to that, he served as the Division Vice President of Quality Assurance for the Critical Care Division at Smiths Medical Critical Care, which develops and manufactures Class I and II anesthesia, respiratory, needle safety devices, and a wide variety of critical care devices. During his career he has also worked at companies such as ACMI Corporation, Genzyme, C.R. Bard and Pfizer.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 1800 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.

For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or via email at ddeptula@icadmed.com

For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at icad@lhai.com

For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release, including but not limited to, statements about the Company's confidence or strategies or expectations about revenues, results of operations, timing of regulatory approval of products or market opportunities, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.


'/>"/>
SOURCE iCAD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
2. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
3. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
4. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
5. Spectral appoints Anthony Bihl to Board of Directors
6. Tianyin Pharmaceutical Appoints Three New Independent Board Members
7. Hiemstra Appoints Robert C. Glines as Director of Business Development
8. Tengion Appoints Jeff Randall to Board of Directors
9. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
10. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
11. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):